International Society for Heart and Lung Transplantation Donation after Circulatory Death Registry, Dallas, Texas.
International Society for Heart and Lung Transplantation Donation after Circulatory Death Registry, Dallas, Texas.
J Heart Lung Transplant. 2015 Oct;34(10):1278-82. doi: 10.1016/j.healun.2015.08.015. Epub 2015 Sep 3.
The objective of this study was to review the international experience in lung transplantation using lung donation after circulatory death (DCD).
In this retrospective study, data from the International Society for Heart and Lung Transplantation (ISHLT) DCD Registry were analyzed. The study cohort included DCD lung transplants performed between January 2003 and June 2013, and reported to the ISHLT DCD Registry as of April 2014. The participating institutions included 10 centers in North America, Europe and Australia. The control group was a cohort of lung recipients transplanted using brain-dead donors (DBDs) during the same study period. The primary end-point was survival after lung transplantation.
There were 306 transplants performed using DCD donors and 3,992 transplants using DBD donors during the study period. Of the DCD transplants, 94.8% were Maastricht Category III, whereas 4% were Category IV and 1.2% Category V (euthanasia). Heparin was given in 54% of the cases, donor extubation occurred in 90% of the cases, and normothermic ex vivo lung perfusion (EVLP) was used in 12%. The median time from withdrawal of life support therapy (WLST) to cardiac arrest was 15 minutes (5th to 95th percentiles of 5 to 55 minutes), and from WLST to cold flush was 33 minutes (5th to 95th percentiles of 19.5 to 79.5 minutes). Recipient age and medical diagnosis were similar in DCD and DBD groups (p = not significant [NS]). Median hospital length of stay was 18 days in DCD lung transplants and 16 days in DBD transplants (p = 0.016). Thirty-day survival was 96% in the DCD group and 97% in the DBD group. One-year survival was 89% in the DCD group and 88% in the DBD group (p = NS). Five-year survival was 61% in both groups (p = NS). The mechanism of donor death within the DCD group seemed to influence recipient early survival. The survival rates through 30 days were significantly different by donor mechanism of death (p = 0.0152). There was no significant correlation between the interval of WLST to pulmonary flush with survival (p = 0.11).
This large study of international, multi-center experience demonstrates excellent survival after lung transplantation using DCD donors. It should be further evaluated whether the mechanism of donor death influences survival after DCD transplant.
本研究旨在回顾国际上使用循环死亡(DCD)供体进行肺移植的经验。
本回顾性研究分析了国际心肺移植协会(ISHLT)DCD 登记处的数据。该研究队列包括 2003 年 1 月至 2013 年 6 月期间进行的 DCD 肺移植,截至 2014 年 4 月已向 ISHLT DCD 登记处报告。参与机构包括北美、欧洲和澳大利亚的 10 个中心。对照组为同期使用脑死亡(DBD)供体进行肺移植的肺受体。主要终点为肺移植后的存活率。
在研究期间,共进行了 306 例 DCD 供体肺移植和 3992 例 DBD 供体肺移植。DCD 移植中,94.8%为马斯特里赫特 III 类,4%为 IV 类,1.2%为 V 类(安乐死)。54%的病例给予肝素,90%的病例拔管,12%的病例使用常温离体肺灌注(EVLP)。从生命支持治疗(WLST)停止到心脏骤停的中位时间为 15 分钟(5 至 95 百分位数为 5 至 55 分钟),从 WLST 到冷冲洗的中位时间为 33 分钟(5 至 95 百分位数为 19.5 至 79.5 分钟)。DCD 和 DBD 组的受体年龄和医学诊断相似(p=无显著差异[NS])。DCD 肺移植的中位住院时间为 18 天,DBD 肺移植为 16 天(p=0.016)。DCD 组 30 天存活率为 96%,DBD 组为 97%。DCD 组 1 年存活率为 89%,DBD 组为 88%(p=NS)。两组 5 年存活率均为 61%(p=NS)。DCD 组供体死亡机制似乎影响受体早期存活率。通过供体死亡机制,30 天内的生存率差异有统计学意义(p=0.0152)。WLST 至肺冲洗的时间间隔与生存率无显著相关性(p=0.11)。
这项来自国际多中心的大型研究表明,使用 DCD 供体进行肺移植具有优异的存活率。还需要进一步评估供体死亡机制是否影响 DCD 移植后的生存率。